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Summary The novel compound 7-[4'-(2-nitroimidazol-l-yl)-butyl]-theophylline (NITP) can be used as an
immunologically detectable probe for hypoxic cells. Because of the limited water solubility of NITP, it has
been administered dissolved in peanut oil with 10% dimethylsulphoxide (DMSO). A new aqueous formulation
has been devised, based on a 50% solution of a modified P-cyclodextrin (Molecusol HPB), which increases the
water solubility of NITP 10-fold. The pharmacokinetics of NITP in plasma and tumours have been compared
following oral and intraperitoneal (i.p.) administration of the NITP in Molecusol, i.p. administration of NITP
dissolved in peanut oil + 10% DMSO and injection of a near-saturated aqueous solution of the drug
intravenously via the tail vein or i.p. or directly into the tumours. Binding of the marker to hypoxic cells
within tumours was also measured after the different routes of administration. The Molecusol vehicle was
unexpectedly toxic when administered i.p., but there was no toxicity from NITP dissolved in Molecusol when
administered orally. Binding of the drug within tumours was seen for both the peanut oil + 10% DMSO and
Molecusol formulations and for both oral and intraperitoneal routes. Binding of NITP within tumours has
also been observed following direct injection of the drug, with minimal whole-body exposure to NITP.
However, the bound metabolites of NITP within tumours were localised to the injection site, suggesting that
direct injection is unlikely to be a useful method of administering bioreductive hypoxia markers. The data in
this paper demonstrate that bound metabolites of the hypoxia marker NITP can be detected in tumours
following oral administration of an aqueous formulation of NITP, and suggest that oral administration could
be a satisfactory administration route for clinical studies with NITP.
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The presence of poorly oxygenated cells in tumours is
thought to be one of the causes of radioresistance in cancer
radiotherapy (Gray et al., 1953), and measurements of
tumour oxygenation have been shown to predict the response
of tumours to radiotherapy (Bush et al., 1978; Gatenby et al.,
1988; Overgaard, 1992). Tumour hypoxia has also been
shown to influence the efficacy of many chemotherapeutic
agents. In particular, bioreductive drugs are specifically
activated in hypoxic cells and can target those cells that are
resistant to radiotherapy (for review see Stratford, 1992).
Numerous methods have been proposed for measuring
tumour hypoxia (for review see Hodgkiss and Wardman,
1992), in the hope that this would allow treatment to be
optimised for individual patients on the basis of the oxygen
status of their tumours. In particular, the hypoxia-specific
binding of isotopically labelled 2-nitroimidazoles has been
used to identify hypoxic cells in tumours, (e.g. Chapman et
al., 1982; Franko and Chapman, 1982; Garrecht and Chap-
man, 1983; Raleigh et al., 1985; Rasey et al., 1985; Urtasun
et al., 1986). Immunological detection of 2-nitroimidazoles
has been described (Raleigh et al., 1987; Hodgkiss et al.,
1991; Lord et al., 1993) and avoids the administration of
radioactive labels, which would be particularly desirable for
clinical measurement of tumour hypoxia.
The novel compound 7-[4'-(2-nitroimidazol-1-yl)-butyl]-
theophylline (NITP), has been described as an immuno-
logically detectable bioreductive probe for hypoxic cells
(Hodgkiss et al., 1991), and appears to offer promise as a
method of quantifying tumour hypoxia in vivo. However, the
water solubility of NITP is only c. 2 x 10-3 M at 20'C and its
administration in vivo, dissolved in water or saline, would
require an inconveniently large volume of drug solution to be
given to achieve an adequate dose level of c. 0.45lsmol g-'.
To circumvent this problem, NITP has been administered in
vivo as a solution in peanut oil + 10% DMSO (Hodgkiss et
al., 1991). While this formulation has given satisfactory
results in the tumour models used, it is clearly unsuitable for
clinical administration, and an aqueous preparation of the
drug would be preferable.
,-Cyclodextrin consists of seven glucose units joined into a
ring, taking up the shape of a three-dimensional torus with a
hydrophobic cavity. 'Guest' molecules of a suitable size can
fit into the central cavity, and the inclusion complex thus
formed can increase the aqueous solubility of lipophilic com-
pounds (Szejtli, 1982). Although P-cyclodextrin is not very
water-soluble, chemically modified derivatives are available
with greatly increased water solubility. This paper describes
the use of a modified 2-hydroxy-propyl-p-cyclodextrin (Mole-
cusol HPB) as an agent for preparing aqueous solutions of
NITP. Comparisons are made between the in vivo plasma
and tumour pharmacokinetics and binding of NITP in
tumour cells using oral and intraperitoneal (i.p.) routes of
administration of this new formulation, and with i.p. admin-
istration using peanut oil + 10% DMSO as a vehicle. Data
are also presented on the results of intratumoral (i.t.), intra-
venous (i.v.) and i.p. injection of a 2 x 10-3 M solution of
NITP in saline.
Materials and methods
Chemicals
The novel compound 7-[4'-(2-nitroimidazol-1-yl)-butyl]-theo-
phylline (NITP) was custom synthesised by Lancaster Syn-
thesis using similar methods to those previously described
(Long et al., 1991). 2-Hydroxypropyl-,-cyclodextrin (Mole-
cusol HPB) was obtained from Bioquote. Dimethyl sulphox-
ide (DMSO) and other reagents were BDH AnalaR grade.
In vivo studies
(a) Tumours The carcinoma CaNT used in this study is a
poorly differentiated mammary carcinoma of spontaneous
origin, which is maintained by serial passage in CBA mice.
The CaNT tumour has a volume doubling time of less than 3
days. Tumours were implanted in the dorsal subcutaneous
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1995site and were used at a mean diameter of 10 mm calculated
from three orthogonal measurements. These studies were
performed under the regulations stipulated by the Animals
(Scientific Procedures) Act (1986).
(b) Drug administration The hypoxia probe NITP, was
administered at various doses by the oral, i.p., i.v. and i.t.
routes. A number of vehicles were employed: peanut oil +
10% DMSO, 0.44 M Molecusol, or saline. For the peanut oil
+ 10% DMSO, the drug was dissolved at 4 x 10-2 M, and
administered i.p. at either 0.45 or 0.09 ytmol g-' (0.01 1,
0.0022 ml g-' respectively). Solutions of Molecusol HPB
(0.44 M) (Molecusol) were prepared and NITP dissolved at
2 x 10-2 M in the solution of Molecusol by heating at 50°C.
The solution of NITP in Molecusol was administered at
room temperature, orally or i.p. at 0.9 (oral only), 0.45 or
0.09 ttmol g' (0.044, 0.022, 0.0044 ml g' respectively). Int-
ravenous and i.p. administrations were also made using a
2 x 1O- M solution in saline at doses of 0.015 and
0.005 ytmol g-' (i.v. only) (0.0075, 0.0025 ml g-l respectively).
The same vehicle was used for i.t. administration, when a
total volume of 0.1 ml (c. 0.006 ytmol g-') was given. Follow-
ing administration of the drug, animals were air breathing
and unrestrained, with a normal supply of food and water.
(c) Tissue preparation and analysis Animals were sacrificed
by decapitation, a blood sample collected in heparinised
tubes and plasma separated by centrifugation. Tumours were
excised and divided into two portions, for pharmacokinetic
measurements and flow cytometry. In some experiments,
samples of liver were also taken for analysis. Plasma and
tissue concentrations of NITP were determined by HPLC as
previously described (Hodgkiss et al., 1991), except that a
26% acetonitrile-water solvent mixture was used to improve
separation of the metabolite peaks. Half-lives were calculated
by linear least-squares regression of logarithmically trans-
formed plasma concentrations. Areas under the curves
(AUCs) were derived by the trapezium rule.
The method of preparing fixed single cell suspensions in
70% ethanol from tumours, immmunohistochemically detect-
ing bound adducts of NITP in the cells and quantifying them
by flow cytometry has also been described (Hodgkiss et al.,
1991). Briefly, bound metabolites of NITP are identified in
fixed single cells prepared from tumours with a primary
rabbit polyclonal antiserum raised against theophylline and a
FITC-labelled goat second antibody raised against rabbit
IgG. Drug binding in tumours is assessed as the proportion
of cells with staining exceeding a threshold, which is set by
control cells not exposed to NITP but treated in parallel with
the immunological reagents. For frozen section an immuno-
peroxidase-conjugated second antibody was used with Vector
purple (Vector Labs) as the immunoperoxidase substrate and
a methyl green counterstain.
(d) Physiology Relative blood flow was assessed in tumours
and normal tissues by measuring rubidium-86 chloride
uptake (Sapirstein, 1958), 1 h after i.p. administration of the
peanut oil + 10% DMSO and 20 min after oral administra-
tion of the Molecusol formulations. Animals were killed by
cervical dislocation 90 s after administration of the radio-
active tracer and samples of tumours and normal tissues
rapidly removed. The rubidium-86 content of the samples
was measured in an LKB Wallac 1282 gamma counter.
Haematuria was monitored with Multistix reagent strips
from Bayer Diagnostics.
Results
High-performance liquid chromatography (HPLC) analysis
showed that two metabolites of NITP appeared in the
plasma with an absorbance at 326 nm (Figure 1), suggesting
that both metabolites include the 2-nitroimidazole ring.
Although extinction coefficients are not available for the two
compounds at the detection wavelength, the similarity of
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Figure 1 (a) HPLC analysis of a methanol extract of mouse
plasma 20 min after i.p. administration of 0.45jlmol g-' NITP in
Molecusol. a, NITP; b, benznidazole internal standard; c,
metabolite 1; d, metabolite 2. (b) Absorption spectra of (
NITP, (-- -) metabolite 1, (. .) metabolite 2. Absorbances at
326 nm relative to NITP are: metabolite 1, 0.042; metabolite 2,
0.245.
their spectra to that of NITP suggests that their E326 values
are likely to be comparable allowing an estimate of their
concentration to be made.
The flow cytometric analysis of bound metabolites in cells
from tumours is illustrated in Figure 2. A region was set on
the background fluorescent staining of cells from tumours
not exposed to NITP so that 1% of the total cells were
within this region (Figure 2a). This region was then used to
estimate the proportion of the population containing bound
metabolites of NITP in cells from tumours exposed to NITP
in vivo (Figure 2b and c). Higher levels of fluorescent binding
were generally observed in tumours treated with 0.45ymol
g-' NITP (Figure 2c) compared with 0.09 tmol g' NITP,
but mean fluorescence is not a sensitive measure of drug
binding as it is biased by the low binding in the well-
oxygenated majority of cells in the tumour. The pharmaco-
kinetics of NITP in plasma and tumours and binding of
metabolites in tumours, following different methods of
administration, is presented in Figures 3-8, Table I. Where
levels of NITP were measured in liver they were similar to
those observed in tumours (Figure 4a). Higher levels of
metabolites, particularly metabolite 2, were found in liver
than in the plasma, indicating that liver metabolism was
responsible for the production of these metabolites (Figure
4a and b). As these metabolites are diffusible and distributed
throughout the body by the plasma, they are unlikely to be
responsible for the localised binding of metabolites of NITP
that is observed in the hypoxic regions of tumours.
Use of peanut oil + 10% DMSO as a vehicle for i.p.
administration of NITP has been described previously
(Hodgkiss et al., 1991). This method of administering NITP
had little effect on physiological parameters such as body
temperature, breathing rate and tumour blood flow (Hodg-
kiss et al., 1991), Table II. When 0.45 lmolg-' NITP is
administered in peanut oil + 10% DMSO, the NITP in the
plasma reaches a stable plateau level of c. 1 x 10-4 M within
10-15 min and then remains at this level for about 50min
(Figure 3a). This 'slow release' effect probably reflects slow
uptake of NITP from a non-aqueous phase, and the subse-
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Figure 2 Typical flow cytometry contour plot of single cells
isolated from CaNT tumours, immunohistochemically stained to
identify bound metabolites of NITP and stained with 1.5 x
10-1 M propidium iodide for the DNA content. (a) Cells from a
tumour not exposed to NITP. The region includes 1% of the
total cells. (b) Cells from a tumour excised 30min after oral
administration of 0.09 ,Lmol g-1 NITP in Molecusol. The region
contains 17% of the total cells. (c) Cells from a tumour excised
90 min after oral administration of 0.45 tLmol g-' NITP in
Molecusol. The region contains 19% of the total cells.
quent balance between uptake and elimination reduces the
peak plasma concentration to about 20% of that predicted
from a uniform distribution of the quantity of the compound
administered. Levels of NITP achieved in tumours were
slightly lower than obtained in the plasma, but the time
course of uptake and loss was generally similar to that in the
plasma. Levels of the two metabolites increased more slowly
in the plasma than the parent compound, and appeared to be
cleared somewhat more slowly. Binding of NITP to cells in
tumours began c. 30 min after i.p. administration of the drug
in the peanut oil + 10% DMSO, reaching a plateau after
about 60min (Figure 3b).
The solubility of NITP in Molecusol was 2.5 x 10-2 M at
500C and 1.7 x 10-2 M at 20°C, corresponding to a c. 10-fold
improvement in the solubility of NITP over that in water
alone. When administered orally to mice at up to 0.9 ymol
g NITP in Molecusol (20tmol g 1), this formulation was
well tolerated with no obvious toxicity. There was little effect
of either vehicle alone or vehicle with drug on the relative
blood flow through tumours, muscle, skin and gut (Table II).
A small elevation of blood flow in the kidney may be related
to the elimination of the water from the vehicle. Lower doses
of NITP (0.45 and 0.09 glmol g 1) in Molecusol led to rela-
tively rapid uptake into the plasma (Figures 4-5), but clear-
ance from the plasma was also rapid with a half-life of
22 min, leading to a relatively small area under the curve and
peak levels similar to those after the peanut oil + 10%
DMSO, but only c. 20% of that expected from a uniform
distribution of the drug. Much of the drug may have been
removed by first-pass hepatic metabolism following uptake
Figure 3 Pharmacokinetics and binding of NITP (0.45 imol
g-'), administered i.p. in peanut oil + 10% DMSO, to CBA
male mice carrying CaNT tumours. (a) NITP concentrations in
plasma (@) and tumours (0). Metabolites in plasma assuming
similar extinction coefficients at 326 nm to NITP: (A), metabolite
1; A, metabolite 2. The half-life of NITP in the plasma was
calculated by linear least-squares regression of logarithmically
transformed plasma concentrations for the time points indicated
by the line. (b) Bound adducts of NITP in cells from tumours,
assessed by fluorescent immunochemical staining and flow
cytometry. Points represent means and standard errors from
three replicate animals.
from the stomach. However, the 'tail' on the pharmaco-
kinetic profile suggests that a proportion of the drug
remained in the digestive tract and was released only slowly.
Considerable variation in the proportion of cells binding
NITP metabolites was observed between tumours from
different transplants after both high- (0.45 l.mol g 1) and
low- (0.09 ymol g- ) oral doses of NITP (Figures 4c and 5b),
even though drug delivery assessed by HPLC analysis of
plasma and tumours was very similar (data not shown).
Intraperitoneal administration of the Molecusol vehicle
alone was unexpectedly toxic (five out of six fatalities) within
24 h after a Molecusol dose of 4.8 l.mol g-'. A solution of
Molecusol in 0.45% saline was slightly less toxic (two out of
six fatalities) at the same dose. At reduced i.p. doses of 3.2
and 1.6jAmol g- , Molecusol in water appeared to be well
tolerated, although some haematuria occurred after doses of
3.2 tLmol g- . Intraperitoneal administration of NITP at 0.45
and 0.09 ytmol g'i (corresponding to 9.9 and 2.0 imol g'I
Molecusol respectively) led to rapid uptake into the plasma,
with a much higher bioavailability (Figures 6 and 7). The
slower clearance of the drug at the higher dose probably
reflects the toxicity of the vehicle and the consequent reduc-
tion in body temperature of the animals. Similar proportions
of cells binding NITP metabolites were observed when NITP
was administered in either Molecusol or peanut oil + 10%
DMSO, despite the toxicity of Molecusol administered i.p. at
the higher dose level. The 5-fold reduction in dose of NITP
(0.45-0.09 jimol g- ) administered in Molecusol had little
effect on the assessment of the proportion of cells binding
NITP.
These data may be compared with data for i.v. and i.p.
injection of a dose of 0.015 or 0.005 molg'1 administered
as a 2 x 10-3 M solution of NITP in saline (Figure 8a).
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Figure 5 Pharmacokinetics and binding of NITP (0.09 limol
g '), administered orally in Molecusol, to CBA male mice carry-
ing CaNT tumours. (a) NITP concentrations in plasma (0) and
4 It tumours (0). Metabolites in plasma assuming similar extinction
0 coefficients at 326 nm to NITP: (A), metabolite 1; (A),
metabolite 2. The half-life of NITP in the plasma was calculated
150 200 250 by linear least-squares regression of logarithmically transformed
n) plasma concentrations for the time points indicated by the line.
__ (b) (0), (0), Bound adducts of NITP in cells from tumours from
Figure 4 Pharmacokineticg and binding of NITP (0.451imol
g-1), administered orally in Molecusol, to CBA male mice carry-
ing CaNT tumours. (a) NITP concentrations in plasma (0) and
tumours (0). Metabolites in plasma assuming similar extinction
coefficients at 326 nm to NITP: (A), metabolite 1; (A),
metabolite 2. The half-life of NITP in the plasma was calculated
by linear least-squares regression of logarithmically transformed
plasma concentrations for the time points indicated by the line.
(b) NITP concentrations in liver (0). Metabolites in liver assum-
ing similar extinction coefficients at 326 nm to NITP: (A),
metabolite 1; (A), metabolite 2. (c) (0,0, A), Bound adducts
of NITP in cells from tumours from three experiments, assessed
by fluorescent immunochemical staining and flow cytometry.
Points represent means and standard errors from three replicate
animals.
Delivery of drugs by i.v. injection can be regarded as nearly
instantaneous, thus eliminating the phase of drug uptake.
Following i.v. or i.p. injection, the plasma half-life of NITP
can be seen to be relatively short. The value quoted for
0.015Itmol g- in Table I is a linear fit to the terminal
elimination phase consistent with the other data in the table.
Non-linear regression gave a biphasic curve with a short
distribution phase with a half-life of 1.7 min, and an elimina-
tion half-life of9.2 min, similar to that shown in Table I. The
volume of distribution using these data was 0.63 ml g I+
0.05 ml g' I (s.e.m.). Intraperitoneal administration also
resulted in rapid uptake and elimination. Direct injection of
2 x 10-3 M NITP into tumours was also carried out in an
attempt to administer the drug locally while reducing the
overall whole-body exposure. Single injections of 0.1 ml into
tumours of c. 10 mm mean diameter gave local tumour con-
centrations of 1 X 10-0M, averaged over the tumour, with
plasma concentrations at least a factor of 20 below this level
(Figure 8b). Plasma clearance was relatively rapid and similar
to that obtained following i.v. injection, while clearance from
the tumour appeared to be somewhat slower.
There was little binding of NITP in tumours after i.v.
injection of a 2 x 10-3M solution of the drug, probably
reflecting the small quantity of drug that could be admini-
two experiments, assessed by fluorescent immunochemical stain-
ing and flow cytometry. Points represent means and standard
errors from three replicate animals.
stered. However, direct injection of a 2 x 10-' M solution of
NITP into tumours led to substantial binding. The distribu-
tion of NITP in frozen section of such tumours, compared
with those obtained following systemic administration
(Figure 9a and b), suggests that much of the metabolic
binding reflected either very high local drug concentrations at
the site of injection, or hypoxia induced locally. Uneven
binding was also observed following injection of 0.033 ml
into each of three sites on the tumour with 5 min between
each injection.
Discussion
As observed previously (Hodgkiss et al., 1991), complete
absorption of NITP from the peritoneal cavity using peanut
oil + 10% DMSO was relatively slow, probably due to the
low solubility of the compound in the vehicle in the aqueous
environment of the peritoneum. This would give a reservoir
exhibiting zero-order absorption kinetics and lead to the slow
clearance seen (Table I). The other routes of administration
resulted in much less evidence of delayed absorption (Figures
4-8), with the exception of the high-dose i.p. Molecusol,
when the toxicity ofthe vehicle, which caused a rapid drop in
body temperature, may have resulted in reduced blood flow.
The elimination half-life was also extended for this dose, and
the cooling may also have been responsible for the very large
plasma AUC, which was more than an order of magnitude
greater than for the lower dose administered by the same
route. The short half-life seen at the low aqueous doses may
reflect some saturation of an elimination mechanism at
higher plasma concentrations, although apparent slower
clearance may also result from continued absorption of drug
from the other vehicles.
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Figure 6 Pharmacokinetics and binding of NITP (0.45 lmol
g '), administered i.p. in Molecusol, to CBA male mice carrying
CaNT tumours. (a) NITP concentrations in plasma (0) and
tumours (0). Metabolites in plasma assuming similar extinction
coefficients at 326 nm to NITP: (A), metabolite 1; (A),
metabolite 2. The half-life of NITP in the plasma was calculated
by linear least-squares regression of logarithmically transformed
plasma concentrations for the time points indicated by the line.
(b) Bound adducts of NITP in cells from tumours, assessed by
fluorescent immunochemical staining and flow cytometry. Points
represent means and standard errors from three replicate animals.
In almost all cases, there appears to be a very slow ter-
minal elimination which could result from a small, slowly
absorbed pool of the drug, or from some hepatobiliary secre-
tion. The two metabolites detected have retained the 326 nm
absorption characteristic of nitroimidazoles, and would
appear from their chromatographic behaviour to be more
polar than the parent compound. However, their elimination
profiles would suggest that they are cleared somewhat more
slowly than NITP. These diffusible metabolites are unlikely
to be those responsible for binding in hypoxic tumour cells.
Bound adducts of the probe identified in tumour cells by
immunofluorescent staining are probably derived from un-
identified reactive metabolites of the 2-nitroimidazole moiety
of NITP.
Bioreductive binding ofNITP occurs mainly in the absence
of oxygen (Hodgkiss et al., 1991) and therefore reflects the
amount of hypoxia in tumours. Some variation is expected in
the amount of hypoxia in individual tumours, and a propor-
tion of the variability in the amount of NITP bound in each
tumour presumably reflects inter-tumour differences in
hypoxic cell fraction. However, variability has also been
observed in the time course and extent of drug binding
between groups of tumours from separate experiments, and
this complicates the detailed interpretation of individual time
courses of drug binding. A single tumour transplant, Figures
4c and 5b (0), exhibited a greater proportion ofcells binding
NITP than in the other six transplants used in this work and
in many transplants used in previous experiments, suggesting
that in this transplant the tumours were more hypoxic than
average. The plasma and tumour pharmacokinetics of the
NITP were virtually identical for the repeat experiments in
which less drug binding was observed. Thus, differences in
the proportions of cells binding NITP in the different trans-
plants do not reflect differences in drug delivery. All other
0 50 100 150
Time (min)
200 250
Figure 7 Pharmacokinetics and binding of NITP (0.09 1tmol
g '), administered i.p. in Molecusol, to CBA male mice carrying
CaNT tumours. (a) NITP concentrations in plasma (0) and
tumours (0). Metabolites in plasma assuming similar extinction
coefficients at 326 nm to NITP: (A), metabolite 1; (A),
metabolite 2. The half-life of NITP in the plasma was calculated
by linear least-squares regression of logarithmically transformed
plasma concentrations for the time points indicated by the line.
(b) Bound adducts of NITP in cells from tumours, assessed by
fluorescent immunochemical staining and flow cytometry. Each
point represents the mean and standard error of data from three
replicate animals.
groups in Figures 3b-7b are derived from individual separ-
ate transplants and the proportion of cells binding NITP is
more consistent despite the different methods of administra-
tion and doses of NITP, and is typical of those seen in many
other transplants in previous work.
The drug binding in tumours is assessed as the proportion
of cells with staining exceeding a threshold, which is set by
control cells not exposed to NITP. This is not a direct
measure of the intensity of staining, nor of the absolute level
of adducts binding in each cell. Nevertheless, the intensity of
staining relative to the background staining in the control
cells contributes to the assessment of drug binding by deter-
mining whether the fluorescence from each cell exceeds the
threshold. Thus, the time course of drug binding partly
reflects the time taken for sufficient drug to bind to exceed
the threshold set on control staining. It is therefore encourag-
ing that a 5-fold reduction in the dose of NITP administered
by oral and i.p. routes did not reduce the intensity of staining
sufficiently to affect the proportion of cells identified as hav-
ing positive staining. This suggests that variability in drug
delivery is not a major factor influencing identification of
hypoxic cells by this method.
Alternative methods of analysing the flow cytometric data
have been examined, but have been found to be relatively
insensitive. The mean fluorescence of the entire cell popula-
tion is dominated by the low fluorescence of the majority of
the relatively well-oxygenated cells in tumours. Similarly, the
mean fluorescence of the positively stained cells in the region
above the background staining is exceedingly insensitive to
the number of cells in the region.
Initial work with NITP used peanut oil + 10% DMSO as
a vehicle for i.p. administration, and this vehicle appeared to
release the drug relatively slowly, giving a constant plasma
concentration over the first hour after administration. How-
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Figure 8 Pharmacokinetics of NITP administered as a 2 x 10-3 M
solution in saline, to CBA male mice (a) NITP concentrations in
plasma following i.v. injection, 0.015 Lmol g' (0), 0.005 lmol
g-I (@) and following i.p. injection 0.015 JAmol g I(A). The half
life of NITP in the plasma was calculated by linear least-squares
regression of logarithmically transformed plasma concentrations
for the time points indicated by the line. (b) NITP concentrations
following i.t. injection (0.1 ml 10mm-' diameter tumour c.
0.006timol g- ); (0), plasma and (0), tumours. Each point
represents the mean and standard error of data from three rep-
licate animals. The half-life of NITP in the plasma was calculated
by linear least-squares regression of logarithmically transformed
plasma concentrations for the time points indicated by the line.
Figure 9 Frozen sections of CaNT tumours stained to reveal
areas containing bound metabolites of NITP (purple): (a) After
administration of NITP (0.45 imol g-') in peanut oil + 10%
DMSO. (b) After administration of NITP by direct injection
(0.1 ml, 2 x 10-3M in saline, c. 0.006 smolg- ) into 10mm
diameter tumours. Each panel represents a field 3.2 mm wide.
Table I Plasma pharmacokinetics of NITP following different methods of administration
Peak concentration Halflife _ s.e.m. AUC ± s.e.m. (M min) (x 103)
Administration route Dose + s.e.m. (M) ( x 106) (min) Plasma Tumour
Molecusol HPB orala 0 127 ± 12 22.3 ± 0.4 5.73 ± 0.48 4.62 ± 0.48
Molecusol HPB oralb 0.45 gmolg' 104 ± 8 26.5 ± 0.2 5.41 ± 0.76 4.09 ± 0.51
Molecusol HPB oral 0.09 gAmol g' 16.2 _ 3.7 22.4 ± 0.6 0.543 ± 0.080 0.310 ± 0.063
Molecusol HPB i.p. 0.45pmol g' 401 ± 6.8 36.6 ± 0.7 27.4 ± 2.9 21.2 ± 2.0
Molecusol HPB i.p. 0.09pmol g' 58.2 ± 3.7 19.7 ± 0.3 2.54 _ 0.26 2.01 ± 0.20
Peanut oil/DMSO i.p. 0.45pmol g' 96.3 ± 10 33.1 ± 0.7 9.26 ± 0.95 6.72 _ 0.84
Saline i.v. 0.015pmol g' 1.91 (1 min, n = 1) 9.64 ± 0.07 0.177 ± 0.003
Saline i.v. 0.005 jAmol g' 4.06 (1 min, n = 1) 8.86 ± 0.12 0.041 + 0.005
Saline i.p. 0.015jimol g-' 6.78 ± 0.27 7.84 _ 0.09 0.100 ± 0.005
Saline i.t. 0.006pmol g' 3.68 1.35 9.79 0.17 0.054 0.016 2.64 0.56
aData presented in Figure 3. bPooled data for three experiments.
Table II Relative blood flow in tumour, gut, muscle and kidney, following administration of NITP or vehicle
Treatment Route Tumour Kidney Gut Muscle Skin
0.45jLmolg-' NITP Oral 1.13 ± 0.21 1.70±0.31 0.85 0.15 0.88 0.07 1.07±0.12
+ 9.9 gmol g-' Molecusol
0.09 gmol g-' NITP Oral 0.83 ± 0.29 1.72 ± 0.31 1.46 ± 0.23 0.77 + 0.07 0.99 ± 0.17
+ 2.0tLmol g-'Molecusol
Vehicle alone 9.9tLmol g-' Oral 0.86 ± 0.16 2.16 ± 0.50 0.92 ± 0.14 0.89 + 0.06 0.94 + 0.09
Molecusol
0.45 Amol g-' NITP +peanut i.p. 1.03 ± 0.11 1.23 ± 0.13 0.82 0.08 0.88 0.07 0.98 0.10
oil + 10% DMSO
Vehicle alone i.p. 0.97 ± 0.16 1.36 + 0.21 1.20 _ 0.14 0.83 _ 0.08 1.10 _ 0.14
peanut oil + 10% DMSO
Untreated control 1.00 ± 0.24 1.00 + 0.10 1.00 + 0.17 1.00 + 0.06 1.00 + 0.10
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ever, peanut oil + 10% DMSO was not a good model for
clinical use of NITP and therefore an aqueous formulation
was developed using a modified P-cyclodextrin (Molecusol) as
a solubilising agent. Intraperitoneal administration of NITP
at 0.45ltmol g-' in peanut oil + 10% DMSO or Molecusol
suggested that the rate of drug binding in hypoxic tumour
cells was much slower than the rate ofdelivery of the drug to
the tumour. The latter data may have been compromised by
the unexpected toxicity of Molecusol when given by this
route, possibly reflecting the administration of a large quan-
tity of a vehicle with a high osmotic potential. This toxicity,
which reduced the body temperature of the mice, probably
explains the long plasma half-life of the drug (Table I) and
slow metabolic binding in tumours. When the dose of the
aqueous formulation was reduced by a factor of 5, there was
no toxicity and the rate of drug binding in tumours was
faster.
Oral administration of NITP (0.45pLmol g-') in Molecusol
led to rapid binding of the drug in tumours, despite the
pharmacokinetic data suggesting relatively poor exposure of
the tumour to the drug, indicated by the low AUC (Table I).
Binding was also observed following a reduction in the dose
of NITP to 0.09limol g-'. While there appeared to be fewer
cells containing bound metabolites in tumours left for 2-4 h
after drug administration in the first experiment, there
appeared to be much less reduction in bound drug over the
same time period in the second experiment. The first data set
may simply reflect an unfortunate distribution of hypoxic
fractions within this group of tumours, as bound metabolites
also appear to have been relatively stable over this time
period in other groups of tumours. Much of the immuno-
logically identifiable signal is associated with DNA. Cellular
RNA is routinely digested from samples for flow cytometry
to improve the DNA profiles, and preparation of cell nuclei
from fixed whole cells causes little loss of signal. It is possible
that some apparent early loss in hypoxic fraction reflects
repair of bulky NITP adducts from DNA or turnover of
proteins. Some turnover and loss of cells may alsg be occurr-
ing after they have bound NITP as kinetic studies show that
this tumour has a high cell-loss factor.
Following systemic administration of NITP, metabolic
binding is observed around the edges of the tumour cords, at
a distance of 6-8 cell diameters from the central blood
vessels (Figure 9a, Hodgkiss et al., 1991). Direct i.t. administ-
ration of NITP would not appear to be a practical alterna-
tive route because drug binding appears to be localised to the
injection site (Figure 9b) and is probably an artifact induced
by this method of administering the drug. However, the
proportions of cells binding NITP averaged over the tumour
were similar to those observed after administration of NITP
by other routes. This illustrates how the distribution of
bound drug can be more informative than the average
amount of drug binding in tumours.
Taken together, these data suggest that it may be possible
to use lower doses of NITP to diagnose tumour hypoxia than
had previously been thought possible. Both aqueous formula-
tion of NITP and oral administration of the aqueous pre-
paration are feasible and have been demonstrated to be
compatible with observation of bioreductive binding of the
compound in hypoxic cells in tumours. This suggests that
detection of bound NITP could be feasible in clinical studies
with oral administration of the drug.
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